Is TRVI or OCS more profitable?

Trevi Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Trevi Therapeutics' return on equity of -23.59% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -23.59% -22.64% Oculis -6,777.18% -42.61% -35.23%

Does the media prefer TRVI or OCS?

In the previous week, Oculis had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 20 mentions for Oculis and 16 mentions for Trevi Therapeutics. Oculis' average media sentiment score of 0.65 beat Trevi Therapeutics' score of 0.37 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher valuation & earnings, ATAI or OCS?

Oculis has lower revenue, but higher earnings than Atai Beckley. Oculis is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atai Beckley $4.09M 657.85 -$660.05M -$2.18 N/A Oculis $1.45M 514.22 -$119.44M -$1.74 N/A

Is ATAI or OCS more profitable?

Oculis has a net margin of -6,777.18% compared to Atai Beckley's net margin of -14,938.36%. Oculis' return on equity of -42.61% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -14,938.36% -88.30% -58.88% Oculis -6,777.18% -42.61% -35.23%

Does the media prefer ATAI or OCS?

In the previous week, Oculis had 16 more articles in the media than Atai Beckley. MarketBeat recorded 20 mentions for Oculis and 4 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 1.37 beat Oculis' score of 0.65 indicating that Atai Beckley is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer TARS or OCS?

In the previous week, Oculis had 2 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 20 mentions for Oculis and 18 mentions for Tarsus Pharmaceuticals. Oculis' average media sentiment score of 0.65 beat Tarsus Pharmaceuticals' score of 0.04 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Oculis 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer SUPN or OCS?

In the previous week, Oculis had 12 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 20 mentions for Oculis and 8 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.79 beat Oculis' score of 0.65 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer PBH or OCS?

In the previous week, Oculis had 8 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 20 mentions for Oculis and 12 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 0.99 beat Oculis' score of 0.65 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prestige Consumer Healthcare 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Oculis (OCS) Competitors

$12.86 +0.04 (+0.31%)

As of 12:22 PM Eastern

Compare

OCS vs. TRVI, ATAI, TARS, SUPN, and PBH

Should you buy Oculis stock or one of its competitors? Oculis's main competitors and comparable companies include Trevi Therapeutics (TRVI), Atai Beckley (ATAI), Tarsus Pharmaceuticals (TARS), Supernus Pharmaceuticals (SUPN), and Prestige Consumer Healthcare (PBH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Oculis compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Oculis (NASDAQ:OCS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Trevi Therapeutics has higher earnings, but lower revenue than Oculis. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Oculis	$1.45M	514.22	-$119.44M	-$1.74	N/A

Trevi Therapeutics presently has a consensus target price of $27.08, indicating a potential upside of 47.54%. Oculis has a consensus target price of $38.33, indicating a potential upside of 198.08%. Given Oculis' higher probable upside, analysts clearly believe Oculis is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Trevi Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Oculis has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Oculis had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 20 mentions for Oculis and 16 mentions for Trevi Therapeutics. Oculis' average media sentiment score of 0.65 beat Trevi Therapeutics' score of 0.37 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Trevi Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Trevi Therapeutics' return on equity of -23.59% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Oculis	-6,777.18%	-42.61%	-35.23%

Summary

Trevi Therapeutics beats Oculis on 11 of the 16 factors compared between the two stocks.

How does Oculis compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Oculis (NASDAQ:OCS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

In the previous week, Oculis had 16 more articles in the media than Atai Beckley. MarketBeat recorded 20 mentions for Oculis and 4 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 1.37 beat Oculis' score of 0.65 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Atai Beckley presently has a consensus target price of $10.56, indicating a potential upside of 45.50%. Oculis has a consensus target price of $38.33, indicating a potential upside of 198.08%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	12 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.20
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oculis has a net margin of -6,777.18% compared to Atai Beckley's net margin of -14,938.36%. Oculis' return on equity of -42.61% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Oculis	-6,777.18%	-42.61%	-35.23%

Atai Beckley has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Oculis has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Oculis has lower revenue, but higher earnings than Atai Beckley. Oculis is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	657.85	-$660.05M	-$2.18	N/A
Oculis	$1.45M	514.22	-$119.44M	-$1.74	N/A

Summary

Oculis beats Atai Beckley on 9 of the 17 factors compared between the two stocks.

How does Oculis compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Oculis (NASDAQ:OCS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Tarsus Pharmaceuticals has higher revenue and earnings than Oculis. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.74	-$66.42M	-$1.09	N/A
Oculis	$1.45M	514.22	-$119.44M	-$1.74	N/A

In the previous week, Oculis had 2 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 20 mentions for Oculis and 18 mentions for Tarsus Pharmaceuticals. Oculis' average media sentiment score of 0.65 beat Tarsus Pharmaceuticals' score of 0.04 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Oculis	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals currently has a consensus price target of $90.50, indicating a potential upside of 30.61%. Oculis has a consensus price target of $38.33, indicating a potential upside of 198.08%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Tarsus Pharmaceuticals has a net margin of -7.67% compared to Oculis' net margin of -6,777.18%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Oculis	-6,777.18%	-42.61%	-35.23%

Tarsus Pharmaceuticals has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Oculis has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Summary

Tarsus Pharmaceuticals beats Oculis on 10 of the 17 factors compared between the two stocks.

How does Oculis compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Oculis (NASDAQ:OCS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, Oculis had 12 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 20 mentions for Oculis and 8 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.79 beat Oculis' score of 0.65 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Supernus Pharmaceuticals has higher revenue and earnings than Oculis. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$830.44M	3.34	-$38.55M	-$1.92	N/A
Oculis	$1.45M	514.22	-$119.44M	-$1.74	N/A

Supernus Pharmaceuticals currently has a consensus price target of $62.83, suggesting a potential upside of 31.78%. Oculis has a consensus price target of $38.33, suggesting a potential upside of 198.08%. Given Oculis' stronger consensus rating and higher probable upside, analysts clearly believe Oculis is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Supernus Pharmaceuticals has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Oculis has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

22.3% of Oculis shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Supernus Pharmaceuticals has a net margin of -13.23% compared to Oculis' net margin of -6,777.18%. Supernus Pharmaceuticals' return on equity of 11.13% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Oculis	-6,777.18%	-42.61%	-35.23%

Summary

Supernus Pharmaceuticals beats Oculis on 9 of the 17 factors compared between the two stocks.

How does Oculis compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and Oculis (NASDAQ:OCS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Prestige Consumer Healthcare has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Oculis has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 1.5% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Prestige Consumer Healthcare has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.09B	2.26	$190.30M	$3.57	14.54
Oculis	$1.45M	514.22	-$119.44M	-$1.74	N/A

In the previous week, Oculis had 8 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 20 mentions for Oculis and 12 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 0.99 beat Oculis' score of 0.65 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prestige Consumer Healthcare	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Prestige Consumer Healthcare has a net margin of 15.57% compared to Oculis' net margin of -6,777.18%. Prestige Consumer Healthcare's return on equity of 11.39% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
Oculis	-6,777.18%	-42.61%	-35.23%

Prestige Consumer Healthcare presently has a consensus target price of $70.75, indicating a potential upside of 36.27%. Oculis has a consensus target price of $38.33, indicating a potential upside of 198.08%. Given Oculis' stronger consensus rating and higher probable upside, analysts clearly believe Oculis is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Prestige Consumer Healthcare beats Oculis on 10 of the 16 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCS vs. The Competition

Export

Metric	Oculis	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$745.68M	$11.72B	$6.98B	$13.03B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	-7.39	783.86	269.56	25.24
Price / Sales	514.22	748.12	596.34	100.74
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	2.68	10.74	13.02	6.32
Net Income	-$119.44M	$2.78B	$3.45B	$347.92M
7 Day Performance	1.42%	-0.29%	0.69%	0.91%
1 Month Performance	-0.54%	-0.17%	1.32%	0.89%
1 Year Performance	-27.75%	160.95%	66.86%	20.28%

Oculis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCS Oculis	3.0101 of 5 stars	$12.86 +0.3%	$38.33 +198.1%	-28.8%	$745.68M	$1.45M	N/A	2	Analyst Revision
TRVI Trevi Therapeutics	2.7218 of 5 stars	$18.74 +4.7%	$24.91 +33.0%	+138.8%	$2.66B	N/A	N/A	20	Analyst Forecast Analyst Revision
ATAI Atai Beckley	3.7729 of 5 stars	$7.17 -0.2%	$11.06 +54.3%	+79.0%	$2.64B	$4.09M	N/A	80	Positive News Earnings Report Analyst Downgrade Short Interest Decrease
TARS Tarsus Pharmaceuticals	3.1101 of 5 stars	$61.09 -0.4%	$90.17 +47.6%	+30.7%	$2.63B	$451.36M	N/A	50	Analyst Forecast Analyst Revision
SUPN Supernus Pharmaceuticals	4.2633 of 5 stars	$42.70 -7.2%	$62.83 +47.2%	+10.6%	$2.48B	$718.95M	N/A	580	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCS) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oculis (OCS) Competitors

OCS vs. TRVI, ATAI, TARS, SUPN, and PBH

How does Oculis compare to Trevi Therapeutics?

Summary

How does Oculis compare to Atai Beckley?

Summary

How does Oculis compare to Tarsus Pharmaceuticals?

Summary

How does Oculis compare to Supernus Pharmaceuticals?

Summary

How does Oculis compare to Prestige Consumer Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oculis (OCS) Competitors

OCS vs. TRVI, ATAI, TARS, SUPN, and PBH

How does Oculis compare to Trevi Therapeutics?

Which has better valuation & earnings, TRVI or OCS?

Do analysts prefer TRVI or OCS?

Which has more volatility & risk, TRVI or OCS?

Do institutionals & insiders believe in TRVI or OCS?

Does the media prefer TRVI or OCS?

Is TRVI or OCS more profitable?

Summary

How does Oculis compare to Atai Beckley?

Does the media prefer ATAI or OCS?

Do insiders and institutionals believe in ATAI or OCS?

Do analysts recommend ATAI or OCS?

Is ATAI or OCS more profitable?

Which has more risk and volatility, ATAI or OCS?

Which has higher valuation & earnings, ATAI or OCS?

Summary

How does Oculis compare to Tarsus Pharmaceuticals?

Which has preferable valuation and earnings, TARS or OCS?

Does the media prefer TARS or OCS?

Do insiders & institutionals hold more shares of TARS or OCS?

Do analysts prefer TARS or OCS?

Is TARS or OCS more profitable?

Which has more volatility and risk, TARS or OCS?

Summary

How does Oculis compare to Supernus Pharmaceuticals?

Does the media prefer SUPN or OCS?

Which has stronger valuation & earnings, SUPN or OCS?

Do analysts rate SUPN or OCS?

Which has more volatility and risk, SUPN or OCS?

Do institutionals and insiders hold more shares of SUPN or OCS?

Is SUPN or OCS more profitable?

Summary

How does Oculis compare to Prestige Consumer Healthcare?

Which has more risk & volatility, PBH or OCS?

Do institutionals and insiders believe in PBH or OCS?

Which has better earnings and valuation, PBH or OCS?

Does the media prefer PBH or OCS?

Is PBH or OCS more profitable?

Do analysts prefer PBH or OCS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools